Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Hospitals & Diagnostics
    • Fortis Healthcare...

    Fortis Healthcare undecided on reopening bidding process

    Written by Ruby Khatun Khatun Published On 2018-05-29T10:15:51+05:30  |  Updated On 29 May 2018 10:15 AM IST
    Fortis Healthcare undecided on reopening bidding process

    BENGALURU: India’s Fortis Healthcare Ltd said it had not decided whether to re-open bidding for itself, after an offer of funding that its board had accepted got a tepid response from investors, prolonging a fierce takeover battle.


    The Hero Enterprise Investment Office and Burman Family Office’s offer this month to invest 18 billion rupees ($267 million) in the company did not go down well with Fortis shareholders, who voted out a director last week. Three directors resigned ahead of the vote.


    The cash-strapped hospital's operator has become an attractive investment target in recent months with five local and international suitors wanting to invest in or buy it, seeking to cash in on an expected boom in India’s private healthcare market.


    Buyout offers from Fortis rival Manipal Health Enterprises and Malaysia’s IHH Healthcare Bhd value Fortis much higher than the Hero-Burman investment offer.


    But the Hero-Burman offer waived due diligence and would give Fortis quick access to funds needed to cut its large debt pile.





    In a letter to Fortis’s board on Monday, the Hero-Burman consortium said it understood some shareholders would prefer that the bidding process be re-opened, and said Fortis had its consent to do so.



    “It appears there may be indecision on the part of the company regarding the bid process,” the consortium said, adding: “We believe that this situation may have arisen largely on account of the lack of information available to stakeholders.”


    After the board had agreed to the Hero-Burman offer, Manipal sweetened its offer to 180 rupees a share, valuing the company at 94.03 billion rupees - higher than the Hero-Burman offer valuing Fortis at 90 billion rupees.




    Malaysia’s IHH, which has proposed injecting 40 billion rupees in Fortis at up to 175 rupees per share, last week extended its offer period until the end of June.




    (Reporting by Tanvi Mehta; Additional reporting by Zeba Siddiqui in Mumbai; Editing by Christopher Cushing and Adrian Croft)




    bidding processBurman Family OfficeFortisFortis HealthcareHero Enterprise Investment OfficeIHH HealthcareManipal Health EnterprisesreopeningtakeoverTakeover Battleundecided
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok